Heller R S, Kieffer T J, Habener J F
Laboratory of Molecular Endocrinology, Massachusetts General Hospital, Howard Hughes Medical Institute, Harvard Medical School, Boston 02114, USA.
Diabetes. 1997 May;46(5):785-91. doi: 10.2337/diab.46.5.785.
Glucagon-like peptide I (GLP-I), an intestine-derived incretin hormone, is a potent stimulator of insulin and somatostatin secretion. In some studies, GLP-I is an inhibitor of glucagon secretion. It remains uncertain, however, whether the effect of GLP-I on the inhibition of glucagon secretion is direct, owing to interactions with GLP-I receptors on alpha-cells, or indirect, via paracrine suppression by insulin or somatostatin. The localization of the GLP-I receptor on insulin and somatostatin-producing cells in the islets is well established. Whether the GLP-I receptor also resides on the glucagon-producing alpha-cells remains controversial and is reported to be absent on rat alpha-cells. To investigate the distribution of the GLP-I receptor on islet cells, we examined the expression of GLP-I receptor mRNA in phenotypically distinct islet cell lines and islets, and the presence of immunoreactive GLP-I receptor in dispersed rat islet cells using a specific antiserum. GLP-I receptor mRNA was readily detected by reverse transcription-polymerase chain reaction (RT-PCR) in both rat islets and in established islet cell lines representing distinct alpha-, beta-, and delta-cell phenotypes. In addition, GLP-I receptor expression was detected in single rat alpha-cells by single-cell RT-PCR. In dispersed rat islet cells analyzed by double immunofluorescent staining, 90% of the insulin, 76% of the somatostatin, and 20% of the glucagon positive cells colocalized with the GLP-I receptor immunoreactivity. Thus, a substantial population of glucagon immunoreactive a-cells express the GLP-I receptor. These findings imply that GLP-I may have a direct receptor-mediated action in the regulation of the physiological functions on a substantial subpopulation of alpha-cells. We suggest that a possible role for GLP-I receptors on alpha-cells may be to provide positive autocrine feedback control on glucagon secretion during fasting and/or to dampen the potent paracrine suppression of glucagon secretion by insulin during feeding.
胰高血糖素样肽I(GLP-I)是一种源自肠道的肠促胰岛素激素,是胰岛素和生长抑素分泌的强效刺激剂。在一些研究中,GLP-I是胰高血糖素分泌的抑制剂。然而,GLP-I对胰高血糖素分泌的抑制作用是直接的(由于与α细胞上的GLP-I受体相互作用)还是间接的(通过胰岛素或生长抑素的旁分泌抑制)仍不确定。GLP-I受体在胰岛中产生胰岛素和生长抑素的细胞上的定位已得到充分证实。GLP-I受体是否也存在于产生胰高血糖素的α细胞上仍存在争议,据报道大鼠α细胞上不存在该受体。为了研究GLP-I受体在胰岛细胞上的分布,我们使用特异性抗血清检测了表型不同的胰岛细胞系和胰岛中GLP-I受体mRNA的表达,以及分散的大鼠胰岛细胞中免疫反应性GLP-I受体的存在情况。通过逆转录聚合酶链反应(RT-PCR)在大鼠胰岛和代表不同α、β和δ细胞表型的已建立的胰岛细胞系中均很容易检测到GLP-I受体mRNA。此外,通过单细胞RT-PCR在单个大鼠α细胞中检测到了GLP-I受体表达。在通过双重免疫荧光染色分析的分散大鼠胰岛细胞中,90%的胰岛素阳性细胞、76%的生长抑素阳性细胞和20%的胰高血糖素阳性细胞与GLP-I受体免疫反应性共定位。因此,大量的胰高血糖素免疫反应性α细胞表达GLP-I受体。这些发现表明,GLP-I可能在调节大量α细胞亚群的生理功能中具有直接的受体介导作用。我们认为,α细胞上GLP-I受体的一个可能作用可能是在禁食期间对胰高血糖素分泌提供正向自分泌反馈控制和/或在进食期间减弱胰岛素对胰高血糖素分泌的强效旁分泌抑制。